# A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

> **NCT02595762** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 110 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Locally Advanced Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02595762
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-30
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595762, "A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02595762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*